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Shifting from egg-based influenza and yellow fever vaccine production towards efficient cell culture-based 
manufacturing is one of the biggest challenges in viral vaccine manufacturing. Innovative bioprocesses, such as 
high cell density [1] or continuous virus cultivations [2] improving cell-based viral vaccine production have been 
shown over the past years. However, finding the right high-yield cell substrate is still pending for many important 
viruses. Ideally, such host cell lines should enable the efficient production of several virus strains to set-up 
manufacturing platforms. 
 
Here, we report on a novel suspension cell line (PBG.PK-21 (ProBioGen) derived from immortal porcine kidney 
cells. These cells were first adapted to chemically defined virus production medium CD-U5 (ProBioGen) and 
agitated suspension culture. Despite its robust growth these cells were not yet suitable for virus manufacture 
due to a chronic infection with porcine circovirus 1 (PCV1) that is often found in porcine cell lines. The cells were 
cured from infection after siRNA mediated suppression of the contaminating virus followed by single cell cloning. 
Clone number 21 proven to be free from PCV1 over multiple passages and distinguished by high peak cell 
densities and good productivity for other viruses was chosen for further analysis. 
 
Cell growth, cell metabolism and virus production were characterized in shake flasks and bioreactors. Cell 
concentration up to 8 x 106 cells/mL and a doubling time of 33 h were obtained in batch mode in CD-U5 
medium. Furthermore, process intensification using either semi-perfusion in shake flasks or hollow fiber-based 
perfusion with an ATF2 system coupled to a 0.6 L wv stirred tank bioreactor system was evaluated. In this 
system, cell densities up to 42 x 106 cells/mL were achieved with a cell-specific perfusion rate of 0.07 
nL/cell/day. 
 
After optimization of influenza A/PR/8/34 (H1N1) virus production, HA titres of 3.3 log(HAU/100µL) with a cell-
specific yield of 5200 virions/cells were achieved in bioreactor fed-batch mode. The PBG.PK-21 suspension cell 
line also shows potential to be used in a modern cell-based swine influenza vaccine production process for the 
veterinary market. Indeed, similar competitive virus titres (3.4 log(HAU/100µL)) and cell-specific yields were 
found for the swine influenza A/Bakum/1832/00 (H1N2) virus in batch mode. Finally, tests were also conducted 
regarding yellow fever virus production (live-attenuated 17DD YFV, RKI). In first scouting experiments, 
promising titres up to 3 x 106 PFU/mL were obtained in batch mode. 
 
First attempts towards process intensification using ATF-based perfusion systems with manually-adapted 
perfusion rate showed successful maintenance of cell-specific influenza A virus yields at high cell density. Titres 
up to 4 log(HAU/100µL) were obtained with 42 x 106 cells/mL. The glycosylation profile of influenza A/PR8/34 
produced in PBG.PK-21 cell line was also analysed and will be compared to profiles of other cell lines. 
 
Overall, PBG.PK-21 suspension cells show a great potential to become the cell substrate of choice for many 
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